Stock Events

Stock Events

Kazia Therapeutics Limited 

€7.25
0
+€0+0% Monday 20:00

Statistics

Day High
7.25
Day Low
7.25
52W High
362.5
52W Low
7.25
Volume
200
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Jan 13
€3.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NV9M.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Agios Pharmaceuticals
AGIO
Mkt Cap1.67B
Agios Pharmaceuticals focuses on cellular metabolism to develop therapies for cancer, competing with Kazia in the cancer metabolism space.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation works on small molecule drugs for oncology, putting it in direct competition with Kazia's therapeutic development.
Exelixis
EXEL
Mkt Cap11.1B
Exelixis, Inc. is involved in developing and commercializing new medicines for difficult-to-treat cancers, making it a competitor in the oncology market.
Array Technologies
ARRY
Mkt Cap1.2B
Array BioPharma specializes in the development of targeted small molecule drugs to treat cancer, directly competing with Kazia's focus.
Novartis
NVS
Mkt Cap279.67B
Novartis is a large pharmaceutical company with a significant oncology division, competing across a broad range of therapeutic areas including those targeted by Kazia.

About

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Show more...
CEO
Dr. John Edwin Friend II, M.D.
Employees
9
Country
Australia
ISIN
US48669G3039

Listings

MU
DE
NV9M.MU
XNAS
US
KZIA
BOATS
BOATS
KZIA.BOATS

0 Comments

Share your thoughts

FAQ

What is Kazia Therapeutics Limited stock price today?▼
The current price of NV9M.MU is €7.25 EUR — it has increased by +0% in the past 24 hours. Watch Kazia Therapeutics Limited stock price performance more closely on the chart.
What is Kazia Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kazia Therapeutics Limited stocks are traded under the ticker NV9M.MU.
Is Kazia Therapeutics Limited stock price growing?▼
NV9M.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Kazia Therapeutics Limited has showed a +0% increase.
Does Kazia Therapeutics Limited pay dividends?▼
Yes, NV9M.MU dividends are paid annual. The last dividend per share was 3.04 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Kazia Therapeutics Limited have?▼
As of May 05, 2026, the company has 9 employees.
In which sector is Kazia Therapeutics Limited located?▼
Kazia Therapeutics Limited operates in the Health & Wellness sector.
When did Kazia Therapeutics Limited complete a stock split?▼
Kazia Therapeutics Limited has not had any recent stock splits.
Where is Kazia Therapeutics Limited headquartered?▼
Kazia Therapeutics Limited is headquartered in Sydney, Australia.